The stock's fall snapped a three-day winning streak.

Vertex Pharmaceuticals (VRTX) ended the recent trading session at $402.49, demonstrating a -1.13% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.55%. On ...

Despite the real problems with the additional indication being sought for suzetrigine, this drop in the stock is still an ...

Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

12月19日，专注于罕见病治疗的药品开发公司Vertex ...

摩根大通：将Vertex Pharmaceuticals的目标价从503美元下调至500美元，但维持“增持”评级。(格隆汇) ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirty-one ratings firms that are covering the firm, ...

We recently compiled a list of the Jim Cramer Discusses 17 Stocks And Blasts Zero Day Options. In this article, we are going ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.